

The UNIVERSITY of SYDNEY

Faculty of Medicine and Health
 School of Medical Sciences
 Charles Perkins Centre
 Sydney NSW 2006, Australia

ariadna.recasens@sydney.edu.au

Phone: + 61 2 8627 6061

Mobile: +61 (0)423 13 620

EDUCATION and TRAINING

2014 - ... Postdoctoral researcher, The University of Sydney

2011-2014 PhD in Neuroscience, Universitat Autònoma de Barcelona, Spain

2009-2011 M.Sc, Neuroscience. Universitat de Barcelona, Spain

2005-2009 B.Sc, Biotechnology. Universitat Rovira i Virgili, Spain

AWARDS AND FELLOWSHIPS

- Professor Tony Basten Fellowship, The University of Sydney (2017-2018, \$50,000)
- Theo Murphy Grant, Australasian Academy of Science EMCR Forum (2018)
- Research Award, Kolling Institute (2016, \$1,500)
- National Stem Cell Foundation of Australia Travel Award (2015)
- NHMRC Science to Art Award –highly commended and featured on the NHMRC website (2014)
- “Paper of the year” mention for my article Recasens et al. (Ann. Neurol, 2014)
- Grant for thesis lecture (\$5,000), from the Agència de Gestió d'Ajuts Universitaris I de Recerca, Spain (2014, \$5,000)
- Best poster presentation, 3rd World Parkinson Congress (2013)
- Pre-doctoral Fellowship from the Agència de Gestió d'Ajuts Universitaris I de Recerca (2011-2014, \$100,000)

PUBLICATIONS

10 publications, 789 citations, h-index 8

1. **Recasens, A** and Munoz L. Targeting Cancer Cell Dormancy. **Trends Pharmacol Sci** 40 (2019) 128-141. *Feature article of the February 2019 issue*. 1 citations
2. **Recasens, A**, Carballo-Carbajal I, Parent A, Bove J, Gelpi E, Tolosa E and M. Vila. Lack of pathogenic potential of peripheral alpha-synuclein aggregates from Parkinson's disease patients. **Acta Neuropathol Commun** 6 (2018) 8. 7 citations
3. Alarcon-Aris, D*, **Recasens A***, Galofre M, Carballo-Carbajal I, Zacchi N, Ruiz-Bronchal E, Pavia-Collado R, Chica R, Ferres-Coy A, Santos M, Revilla R, Montefeltro A, Farinas I, Artigas F, Vila M and Bortolozzi A. Selective alpha-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease. **Mol Ther** 26 (2018) 550-567. **equally contributed*. 9 citations
4. **Recasens, A***, Ulusoy A, Kahle PJ, Di Monte DA and Dehay B. In vivo models of alpha-synuclein transmission and propagation. **Cell Tissue Res** 373 (2018) 183-193. 8 citations. *Invited review and corresponding author*
5. **Recasens, A**, Perier C and Sue CM. Role of microRNAs in the Regulation of alpha-Synuclein Expression: A Systematic Review. **Front Mol Neurosci** 9 (2016) 128. 11 citations

6. **Recasens, A** and Dehay B. Alpha-synuclein spreading in Parkinson's disease. **Front Neuroanat** 8 (2014) 159. 80 citations
7. Bove, J, Martinez-Vicente M, Dehay B, Perier C, **Recasens A**, Bombrun A, Antonsson B and Vila M. BAX channel activity mediates lysosomal disruption linked to Parkinson disease. **Autophagy** 10 (2014) 889-900. 29 citations
8. **Recasens, A**, Dehay B, Bove J, Carballo-Carbajal I, Dovero S, Perez-Villalba A, Fernagut PO, Blesa J, Parent A, Perier C, Farinas I, Obeso JA, Bezard E and Vila M. Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. **Ann Neurol** 75 (2014) 351-362. 246 citations. *Paper of the year and commentary in the Editorial*
9. Ramonet, D, Perier C, **Recasens A**, Dehay B, Bove J, Costa V, Scorrano L and Vila M. Optic atrophy 1 mediates mitochondria remodeling and dopaminergic neurodegeneration linked to complex I deficiency. **Cell Death Differ** 20 (2013) 77-85. 47 citations
10. Dehay, B., Bove J, Rodriguez-Muela N, Perier C, **Recasens A**, Boya P and Vila M. Pathogenic lysosomal depletion in Parkinson's disease. **J Neurosci** 30 (2010) 12535-12544. 351 citations

Under review

11. Abbassi RH, **Recasens A**, Venkata DI, Ferchland A, Johns TG, Stringer BW, Day BW, Munoz L. Tubulin code of glioblastoma stem cells and correlation with sensitivity to microtubule-targeting agents. **British Journal of Cancer**, revision requested by the editor
12. Phoa AF, **Recasens A**, Gurgis FMS, Betts TA, Hoque M, Chau D, Nordfors K, Haapasalo J, Haapasalo H, Johns TG, Stringer BW, Day BW, Buckland ME, Lalaoui N, Munoz L. MK2 inhibition stabilizes wild-type and mutated p53 in glioblastoma cells and leads to different cellular responses. **Neuro-Oncology**, submitted
13. Bourden M, Nioche A, Dovero S, Arotcarena ML, Camus S, Porras G, Thiolat ML, Rougier NP, Prigent A, Aubert P, Bohic S, Kruse N, Mollenhauer B, Novello S, Morari M, Leste-Lasserre T, Damas IT, Goillandeau M, Perier C, Garcia-Carrillo N, Estrada C, Recasens A, Blesa J, Herrero MT, Derkineren P, Vila M, Obeso JA, Dehay B and Bezar E. Machine learning reveals pathological signatures induced by patient-derived alpha-synuclein structures. **Science Translational Medicine**, revision requested by the editor.

FUNDING

1. Sydney Medical School, Professor Tony Basten Fellowship (2017-2018; \$50,000)
Targeting dormant, drug-resistant cancer cells to improve glioblastoma treatment
2. Agència de Gestió d'Ajuts Universitaris I de Recerca (AGAUR, Spain) Pre-doctoral Fellowship (2011-2014; \$100,000)
Initiation, progression and extension of Parkinson's disease: role of α -Synuclein

SUPERVISION and MENTORING

Currently

1. Sean Tan, Honours Student, Bachelor of Medical Science, The University of Sydney
Project: The role of DYRK1A in glioblastoma dormancy
2. Jayden Sterling, Honours Student, Bachelor of Medical Science, The University of Sydney
Project: the role of histone demethylases in glioblastoma persister cells
3. Kudzai Chinjekure, visiting research student, University of Cardiff, UK

4. Mariona Pont, visiting research student, Universitat de Lleida, Spain

Completed

5. Dylan McCuaig-Walton, Honours student, 1st Class Honours and University Medal 2018
Project: Role of DYRK1A in glioblastoma cells differentiation
6. Michael Ellis, visiting research student from University of Bath, UK
Project: Role of DYRK1A in glioblastoma cells proliferation

ORAL PRESENTATIONS

Abstracts selected for plenary sessions in international conferences:

1. A new iPS-derived neuronal model to investigate sodium valproate toxicity in patients with POLG mutations. Annual Meeting of the Australasian Society for Stem Cell Research, Sydney, July 2015
2. Lewy body fractions from patients with Parkinson's Disease initiate synuclein-dependent neurodegeneration in mice and non-human primates. World Parkinson Congress, Montreal, Nov 2013

Research seminars

3. Targeting dormant cancer cells to improve glioblastoma treatment. Charles Perkins Centre, Biology Domain Seminars, 2019

POSTER PRESENTATIONS IN (INTER)NATIONAL CONFERENCES

1. **Recasens A**, Phoa A, and Munoz L. DYRK1A inhibitors to improve the efficacy of glioblastoma treatment. Annual CPC Symposium, Sydney, Sept 2017
2. Galofré M, **Recasens A**, Ruiz-Bronchal E, Ferrés-Coy A, Diana, Revilla R, Montefeltro A, Fariñas I, Vila M, Bortolozzi A. Selective down-regulation of alpha-synuclein in monoaminergic neurons of mice increases synaptic dopamine tone. FENS Forum of Neuroscience, Milan, July 2014
3. **Recasens A**, Galofré M, Carballo-Carbajal I, Bové J, Perier C, Ferrés-Coy A, Carmona M.C, Santos M. I., Baena S, Chica M.R, Montefeltro A, Revilla R, Bartolozzi A and Vila M. Selective silencing of alpha-synuclein in aminergic neurons In vivo by intranasal delivery of targeted small interfering RNA or antisense oligonucleotides: Relevance to Parkinson's disease. Annual Meeting of the Society for Neuroscience, San Diego, Nov 2013
4. **Recasens A**, Dehay B, Bové J, Carballo-Carbajal I, Dovero S, Pérez A, Fernagut P.O, Blesa J, Parent A, Perier C, Fariñas I, Obeso J.A, Bezard E and Vila M. Lewy body fractions from patients with Parkinson's Disease initiate synuclein-dependent neurodegeneration in mice and non-human primates. World Parkinson Congress, Montreal, Nov 2013. *Best poster presentation and abstract selected for oral presented in Hot Topic Session.*
5. Ramonet D, Perier C, **Recasens A**, Dehay B, Bové J, Costa V, Scorrano L and Vila M. Optic atrophy 1 mediates mitochondria remodeling and dopaminergic neurodegeneration linked to complex I deficiency. FENS Forum of Neuroscience, Barcelona, July 2012

PROFESSIONAL AND COMMUNITY ENGAGEMENT CONTRIBUTION

Membership in professional societies

- Co-chair of the Charles Perkins Centre Early- and Mid- Career Researchers Committee

- Member of the Brain and Mind Centre, Early Career Development Initiative
- Member of the Sydney Cancer Network
- Subcommittee Sponsorship and Industry, Australasian Society for Stem Cell Research (2015)
- Kolling Institute Grant Review Panel (2015-2016)
- Kolling institute Seminar committee (2015-2016)
- NHMRC check-compliance team in the Kolling Institute (2015-2016)

Organization of conferences

- Organizing committee and session marking of the International Congress AussieMit2016

Others

<https://cen.acs.org/biological-chemistry/cancer/Microtubule-protein-level-predicts-drugseffectiveness/97/web/2019/09>.